Key facts
- Talus Bio’s last known valuation is $31.2M.
- It has raised $19.6M; the latest was Seed Round ($11.2M) in Aug 2024.
- Notable investors include Y Combinator, Creative Destruction Lab, US National Science Foundation, Pioneer Fund, Gaingels — 46 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 46 names
- ·Watchlist + deal alerts for Talus Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Talus Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Talus Bio
Developer of a data-enabled drug development platform designed to offer small-molecule therapy in oncology. The company's platform combines cell processing with high-sensitivity quantitative proteomics and machine learning analytics, focusing on drug discovery through gene regulation, enabling the healthcare sector to advance drug development for gene control.
- Sector
- Healthcare
- HQ
- Seattle, WA, United States
- Founded
- 2020
- Employees
- 27
- Website
- talus.bio/
- Ownership
- Privately Held (backing)
Talus Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Talus Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Talus Bio in its N-PORT filings yet. We sweep new filings monthly.